摘要
卡博替尼作为一种抑制MET、血管内皮生长因子受体2(VEGFR2)和RET的酪氨酸激酶抑制剂,可阻断肿瘤细胞发生和发展,临床上用于进展性、转移性甲状腺髓样癌(MTC)患者的治疗.文中对卡博替尼的作用机制、药动学、药物相互作用、临床评价和安全性等进行综述.
Abstract
Cabozantinib,a new drug for medullary thyroid cancer treatment,is a potent inhibitor of MET,RET,and vascular endothelial factor receptor 2 (VEGFR2) as well as other tyrosine kinases that have been implicated in tumor development and progression.The mechanism,pharmacokinetics,drug interaction,clinical evaluation,and safety of cabozantinib were reviewed.
NETL
NSTL
维普
万方数据